Genome-wide mutational signatures of aristolochic acid and its application as a screening tool
- PMID: 23926199
- DOI: 10.1126/scitranslmed.3006086
Genome-wide mutational signatures of aristolochic acid and its application as a screening tool
Abstract
Aristolochic acid (AA), a natural product of Aristolochia plants found in herbal remedies and health supplements, is a group 1 carcinogen that can cause nephrotoxicity and upper urinary tract urothelial cell carcinoma (UTUC). Whole-genome and exome analysis of nine AA-associated UTUCs revealed a strikingly high somatic mutation rate (150 mutations/Mb), exceeding smoking-associated lung cancer (8 mutations/Mb) and ultraviolet radiation-associated melanoma (111 mutations/Mb). The AA-UTUC mutational signature was characterized by A:T to T:A transversions at the sequence motif A[C|T]AGG, located primarily on nontranscribed strands. AA-induced mutations were also significantly enriched at splice sites, suggesting a role for splice-site mutations in UTUC pathogenesis. RNA sequencing of AA-UTUC confirmed a general up-regulation of nonsense-mediated decay machinery components and aberrant splicing events associated with splice-site mutations. We observed a high frequency of somatic mutations in chromatin modifiers, particularly KDM6A, in AA-UTUC, demonstrated the sufficiency of AA to induce renal dysplasia in mice, and reproduced the AA mutational signature in experimentally treated human renal tubular cells. Finally, exploring other malignancies that were not known to be associated with AA, we screened 93 hepatocellular carcinoma genomes/exomes and identified AA-like mutational signatures in 11. Our study highlights an unusual genome-wide AA mutational signature and the potential use of mutation signatures as "molecular fingerprints" for interrogating high-throughput cancer genome data to infer previous carcinogen exposures.
Comment in
-
Genomics traces carcinogen fingerprints.Sci Transl Med. 2013 Aug 7;5(197):197fs31. doi: 10.1126/scitranslmed.3006810. Sci Transl Med. 2013. PMID: 23926198
-
Bladder cancer: aristolochic acid--one of the most potent carcinogens known to man.Nat Rev Urol. 2013 Oct;10(10):552. doi: 10.1038/nrurol.2013.186. Epub 2013 Aug 27. Nat Rev Urol. 2013. PMID: 23979661 No abstract available.
Similar articles
-
Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing.Sci Transl Med. 2013 Aug 7;5(197):197ra102. doi: 10.1126/scitranslmed.3006200. Sci Transl Med. 2013. PMID: 23926200 Free PMC article.
-
Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma.Theranostics. 2020 Mar 4;10(10):4323-4333. doi: 10.7150/thno.43251. eCollection 2020. Theranostics. 2020. PMID: 32292497 Free PMC article.
-
Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid.Mutat Res. 2013 Jul-Sep;753(1):41-49. doi: 10.1016/j.mrrev.2013.02.003. Epub 2013 Feb 17. Mutat Res. 2013. PMID: 23422071 Free PMC article. Review.
-
Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes.Int J Cancer. 2013 Jul;133(1):14-20. doi: 10.1002/ijc.28013. Epub 2013 Feb 12. Int J Cancer. 2013. PMID: 23292929
-
Mutational signature of aristolochic acid: Clue to the recognition of a global disease.DNA Repair (Amst). 2016 Aug;44:205-211. doi: 10.1016/j.dnarep.2016.05.027. Epub 2016 May 20. DNA Repair (Amst). 2016. PMID: 27237586 Review.
Cited by
-
Unveiling correlations between aristolochic acids and liver cancer: spatiotemporal heterogeneity phenomenon.Chin Med. 2024 Sep 28;19(1):132. doi: 10.1186/s13020-024-01003-y. Chin Med. 2024. PMID: 39342223 Free PMC article. Review.
-
Comprehensive molecular characterization of collecting duct carcinoma for therapeutic vulnerability.EMBO Mol Med. 2024 Sep;16(9):2132-2145. doi: 10.1038/s44321-024-00102-5. Epub 2024 Aug 9. EMBO Mol Med. 2024. PMID: 39122888 Free PMC article.
-
Molecular Basis of Tumorigenesis of Bladder Cancer and Emerging Concepts in Developing Therapeutic Targets.Bladder Cancer. 2023 Dec 13;9(4):313-322. doi: 10.3233/BLC-230025. eCollection 2023. Bladder Cancer. 2023. PMID: 38994247 Free PMC article. Review.
-
The mutagenic forces shaping the genomic landscape of lung cancer in never smokers.medRxiv [Preprint]. 2024 May 17:2024.05.15.24307318. doi: 10.1101/2024.05.15.24307318. medRxiv. 2024. PMID: 38798417 Free PMC article. Preprint.
-
Geographic variation of mutagenic exposures in kidney cancer genomes.Nature. 2024 May;629(8013):910-918. doi: 10.1038/s41586-024-07368-2. Epub 2024 May 1. Nature. 2024. PMID: 38693263 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
